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Abstract
Retinitis pigmentosa (RP) is a group of photoreceptor degenerative disorders that lead to loss of vision. Typically, rod
photoreceptors degenerate first, resulting in loss of night and peripheral vision. Secondary cone degeneration eventually
affects central vision, leading to total blindness. Previous studies have shown that photoreceptors could be protected from
degeneration by exogenous neurotrophic factors, including ciliary neurotrophic factor (CNTF), a member of the IL-6 family
of cytokines. Using a transgenic rat model of retinal degeneration (the S334-ter rat), we investigated the effects of
Oncostatin M (OSM), another member of the IL-6 family of cytokines, on photoreceptor protection. We found that
exogenous OSM protects both rod and cone photoreceptors. In addition, OSM promotes regeneration of cone outer
segments in early stages of cone degeneration. Further investigation showed that OSM treatment induces STAT3
phosphorylation in Mu ¨ller cells but not in photoreceptors, suggesting that OSM not directly acts on photoreceptors and
that the protective effects of OSM on photoreceptors are mediated by Mu ¨ller cells. These findings support the therapeutic
strategy using members of IL-6 family of cytokines for retinal degenerative disorders. They also provide evidence that
activation of the STAT3 pathway in Mu ¨ller cells promotes photoreceptor survival. Our work highlights the importance of
Mu ¨ller cell-photoreceptor interaction in the retina, which may serve as a model of glia-neuron interaction in general.
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Introduction
Retinitis pigmentosa (RP) is a heterogeneous group of inherited
retinal degenerative disorders that affect one in 3,500 to 4,000
people [1]. Mutations in 40 genes identified so far are implicated
in RP, most of which selectively affect rods (http://www.sph.uth.
tmc.edu/retnet/sum-dis.htm). In early stages of RP, patients
typically experience night blindness and decline in peripheral
vision, due to loss of rod photoreceptors in the peripheral retina. In
many cases even though the mutations do not directly affect cone
photoreceptors, cones undergo secondary degeneration following
rods [1,2]. The secondary cone degeneration eventually affects the
central vision, leading to total blindness. No effective treatments
are currently available for RP. How to effectively protect photo-
receptors, especially cone photoreceptors, is a major challenge in
retinal degeneration research.
Pre-clinical studies have shown that photoreceptors can be pro-
tected by exogenous neurotrophic factors. LaVail and colleagues
[3] first demonstrated in the RCS (the Royal College of Surgeon)
rats that a single injection of FGF-2 successfully rescues
photoreceptors from degeneration [3]. A subsequent screen of a
panel of factors identified several neurotrophic factors that protect
photoreceptors in a light-damaged model, including CNTF (ciliary
neurotrophic factor), a member of the interleukin-6 (IL-6) family of
cytokines [4]. Many studies since confirmed the protective effects
of CNTF in animal models cross several species. These pre-clinical
results led to a phase 1 clinical trial with promising results [5]. Two
other members of the IL-6 family of cytokines, including CT-1
(cardiotrophin 1) and LIF (leukemia inhibitory factor), have been
reported to protect photoreceptors in different animal models
[6,7].
Oncostatin M (OSM), originally isolated from a tumor cell line
and identified as a factor to suppress the growth of tumor cells, is
also a member of the IL-6 family of cytokines [8,9,10]. It expresses
mainly in activated T lymphocytes, monocytes [8,11], but also in
other tissues [12], including in neurons, astrocytes, and microglia
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18282[13]. OSM has a variety of biological effects, including inhibition
of solid tumor cells, inhibition of totipotent embryonic stem cells,
and induction of acute phase protein synthesis in hepatic cells [10].
In the nervous system, OSM induces the expression of IL-6 and
other cytokines, regulates inflammatory reactions as well as matrix
remodeling [13]. It also suppresses brain tumor cells [13]. Elevated
levels of OSM have been detected in several human CNS
pathologies, such as multiple sclerosis, HIV-associated dementia,
and epileptic seizure [14,15,16].
In the present work, we studied the neuroprotective feature of
OSM in a transgenic rat model of retinal degeneration. Our data
show that OSM not only protects both rod and cone photorecep-
tors, but also promotes regeneration of cone outer segments (COS)
in degenerating cones. Furthermore, our results suggest that the
effects of OSM are mediated through the Jak/STAT3 pathway in
Mu ¨ller cells.
Results
Protection of Rod Photoreceptors by OSM
Mature human recombinant OSM, fused to a 6xHis tag at the
amino terminus, was expressed in E. coli, purified by nickel
columns, and buffer exchanged with phosphate buffered saline
(PBS) (see Materials and Methods for details). The purified
recombinant protein has an apparent size of ,25 kD after
electrophoresis in acrylamide gel (Fig. 1). Although OSM is a
glycoprotein, recombinant OSM expressed in E. coli is folded in
the native conformation and fully functional as the native protein
produced in human cells [17].
To examine the effects of OSM on photoreceptor degeneration,
we used the heterozygous S334ter-3 rats as a model of retinal
degeneration with rapid degeneration of rod photoreceptors [18].
Intravitreal injection of OSM (10 mgi n3ml PBS) at PD9 resulted
in significant protection of rod photoreceptors when examined at
PD20. As shown in Fig. 2, the outer nuclear layer (ONL) of the
retina in normal wild type animals has 10–12 rows of
photoreceptor nuclei (Fig. 2A), whereas the ONL of S334ter
animals treated with PBS had only one row (Fig. 2B). In contrast,
OSM-treated retinas typically had 6–8 rows of photoreceptor
nuclei in the ONL (Fig. 2C). Measurement of the ONL thickness
showed that the thickness in the OSM-treated retinas
(23.1161.70 mm, n=3) is significantly greater (P=0.002, Student
t test) than in PBS-treated control retinas (5.2260.19 mm).
Protection of Cone Photoreceptors by OSM
To examine whether OSM protects cone photoreceptors as
well, we used the same rat model in which the secondary cone
degeneration develops following rod degeneration, as has been
characterized recently [19]. In these experiments, eyes of
homozygous S334ter rats were injected with OSM (10 mgi n
3 ml PBS) at PD 20 and retinas were collected at PD 30. COS were
identified by PNA (peanut agglutinin) staining. In the PBS-treated
control retinas, loss of COS was found in numerous small PNA-
negative areas throughout the retina (Fig. 3A). This finding is
consistent with previous observations [19]. In OSM-treated
retinas, the PNA-negative areas became very small and in many
cases completely disappeared (Fig. 3B). Quantitative analysis
showed that the density of PNA-positive cells in the OSM-treated
retinas is 905635.44/0.15 mm
2 (n=6), significantly higher than
that in the PBS-treated retinas (742.83636.14, n=6) (P,0.01,
Student t-test) (Fig. 3C). These results indicate that OSM
Figure 1. Recombinant human OSM. Purified recombinant human
OSM protein was detected as a single band of ,25 kD after
electrophoresis in acrylamide gel and visualized with Coomassie blue.
Left lane: protein molecular mass marker (molecular mass is indicated
on the left for the two bands near the OSM protein); Right lane: 3 mgo f
purified recombinant human OSM protein.
doi:10.1371/journal.pone.0018282.g001
Figure 2. Protection of rod photoreceptors by OSM treatment.
Plastic semi-thin sections of retina were examined by light microscopy.
In wild-type rats, photoreceptors are well developed by PD20 (A). The
ONL contains typically 10–12 rows of nuclei with well-organized outer
and inner segments (A). In the retinas of transgenic rats treated with
PBS (3 ml, injected at PD9 and harvested at PD 20), the ONL had only
one row of nuclei (B). In contrast, more than six rows of nuclei remained
in the ONL in OSM-treated eyes (left eyes of the same rats) (C). The ONL
is indicated by a white vertical bar in each panel. Scale bar, 25 mm.
doi:10.1371/journal.pone.0018282.g002
OSM and Photoreceptor Protection
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degeneration.
COS Regeneration Induced by OSM Treatment
The disappearance of PNA negative areas in the OSM-treated
retinas (Fig. 3B) also suggested to us that OSM promoted
regeneration of COS in cones that had lost COS. To test this
hypothesis, we performed experiments in which retinas were
treated with OSM at PD35 and examined at PD45. As shown in
Fig. 4, it appears that there are more PNA-positive cells in OSM-
treated retinas at PD45 (Fig. 4C) than in untreated retinas at PD
35 (Fig. 4A) or PBS-treated retinas at PD45 (Fig. 4B). Quantitative
analysis showed that indeed, the density of PNA-positive cells in
the OSM-treated retinas at PD45 (665616.56/0.15 mm
2,n=3 )i s
significantly higher than that of the untreated retinas collected at
PD35 (565.3366.36, n=3) (P,0.01, ANOVA and Tukey test) or
PBS-treated retinas at PD45 (464618, n=3) (P,0.001, ANOVA
and Tukey test) (Fig. 4D). The fact that the density of PNA-positive
cells in the OSM-treated retinas at PD45 is higher than that in the
retinas at PD35 provides evidence of COS regeneration in
response to OSM treatment. This finding is consistent with our
previous results with CNTF treatment [19].
Phosphorylation of STAT3 Induced by OSM
We next examined the phosphorylation of STAT3 in the retina
after OSM treatment. A significant increase in STAT3 phosphor-
ylation was detected as early as 30 min after OSM injection
(Fig. 5A). The treatment also induced a small increase in STAT3
protein level in the retina (Fig. 5A). In contrast, PBS injection
induced a much smaller increase with shorter duration in
phosphorylated STAT3 (Fig. 5B), which is consistent with our
previous observations [6].
To localize OSM-induced STAT3 phosphorylation, wild-type
rats were treated with OSM in the left eyes and PBS in the right
eyes. Eyes were collected 1 hour later. Phosphorylated STAT3
was detected in the OSM-treated retina in a group of cells in the
inner nuclear layer (INL). Those cells were also positive for
glutamine synthetase (GS), a Mu ¨ller cell specific marker, (Fig. 6D–
6F, high magnification 6G–6I). The colocalization of pSTAT3
and GS confirms that OSM induces STAT phosphorylation in
Mu ¨ller cells. In contrast, no pSTAT3 was detected in the outer
nuclear layer (ONL) where photoreceptor cell bodies reside,
indicating that photoreceptors are not directly responsive to OSM
(Fig. 6D, 6F). Phosphorylated STAT3 was not detected in the
control retina (Fig. 6A). These results provide evidence that OSM
induces STAT3 activation specifically in Mu ¨ller cells, not in
photoreceptors.
Discussion
The present work has shown that OSM protects both rod and
cone photoreceptors from degeneration. OSM treatment also
promotes regeneration of COS in degenerating cones. We have
further demonstrated that OSM induced STAT3 activation in
Mu ¨ller cells, not in photoreceptors, suggesting that OSM-induced
photoreceptor survival is mediated by Mu ¨ller cells.
OSM is a member of the IL-6 family of cytokines with
significant homology of amino acid sequence and structure with
other members of the family, especially with LIF [9,10,20]. As a
pleiotrophic cytokine, OSM exerts many functions that overlap
those of related cytokines in a variety of systems, including
Figure 3. Protection of cone photoreceptors by OSM treat-
ment. Eyes of homozygous S334ter-3 rats were injected with OSM (left
eyes) or PBS (right eyes) at PD20 and retinas were collected at PD30. In
PBS-treated control eyes, many PNA-negative areas are present (A). In
OSM-treated eyes, the PNA-negative areas became very small and
completely disappeared (B). Quantitative analysis (C) showed that the
density of PNA-positive cells in the OSM-treated retinas (905635.44,
n=6) is significantly higher than in the PBS-treated retinas
(742.83636.14, n=6, P,0.01, Student t-test). Scale bar: 50 mm.
doi:10.1371/journal.pone.0018282.g003
Figure 4. Regeneration of COS induced by OSM. Homozygous
S334ter rats were treated with either OSM or PBS at PD35 as described
in Fig. 3. Eyes were collected at PD45. A group of eyes was collected at
PD35 without treatment as baseline control. There are more PNA
positive cells in OSM treated retinas(C) than in either PBS treated retinas
(B) or untreated retinas of PD35 (A). Quantitative analysis (D) showed
that there are significantly more PNA-positive cells in the OSM-treated
retinas at PD45 (665616.56, n=3) than in the PBS-treated retinas at
PD45 (464618, n=3, P,0.001) or in untreated retinas at PD35
(565.3366.36, n=3, P,0.01). Double-asterisk indicates P,0.01; triple-
asterisk indicates P,0.001 (ANOVA and Tukey test). Scale bar: 50 mm.
doi:10.1371/journal.pone.0018282.g004
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The expression of OSM is found in various tissues, including the
brain [12]. In the brain, OSM expression was reported in
hippocampus [23] and pituitary gland [24]. Upregulation of OSM
is found in multiple sclerosis lesions in the brain in microglia,
reactive astrocytes, infiltrating leukocytes [25], as well as in
peripheral blood mononuclear cells [26]. It is also found in
interneurons and glial cells in the hippocampus after prolonged
seizure [16]. Significant increase in OSM expression was also seen
after sciatic nerve crush or transaction [27]. In the OSM-deficient
mice, there is a significant decrease in neurons in the dorsal root
ganglia [28]. The loss of neurons in the dorsal root ganglia is
accompanied with reduced noxious responses to acute thermal,
mechanical, chemical, and visceral pain, indicating the essential
function of OSM in nociceptor neurons [28]. Furthermore, OSM
have been shown to be neuroprotective in models of excitotoxic
injury [29,30]. Our present finding that OSM protects photore-
ceptors is consistent with OSM being a neurotrophic cytokine,
similar to CNTF, LIF, and CT-1.
TwoOSMreceptorcomplexeshavebeenidentifiedinhumanfor
OSM signal transduction. The type I receptor complex is a
heterodimer of LIF receptor b (LIFRb) and gp130, the same
receptor complex shared by several IL-6 family of cytokines,
including CNTF, LIF, and CT-1 [31,32]. The type II OSM
receptor complex is composed of the OSM specific receptor
OSMRb and gp130. Human OSM binds to both the type I and
type II human receptors [22,33]. This is not the case in mouse,
however. MouseOSMisunabletotransducesignals throughmouse
LIFRb. It uses only the receptor complex of mouse OSMRb and
gp130 for its biological activities. On the other hand, human OSM
can activate mouse LIFRb, but not the mouse OSMRb [33]. In our
experiments, we used recombinant human OSM on rat model of
retinal degeneration. Although it is not clear whether human OSM
interacts with rat OSMRb, it does induce biological effects on rat
cells [34,35]. It is likely that in rat the human OSM effects are also
mediated by the receptor complex of LIFRb and gp130.
The finding that OSM induces STAT3 phosphorylation in
Mu ¨ller cells but not in photoreceptors is in agreement with
previous findings that CNTF and CT-1, two members of the IL-6
family of cytokines, activate the STAT3 pathway in Mu ¨ller cells
but not in photoreceptors [6,36]. These consistent results strongly
suggest that the protective effects of OSM are mediated by Mu ¨ller
cells, which express receptors for cytokines of the IL-6 family [37].
Studies have shown that activation of the STAT3 pathway in
Mu ¨ller cells by CNTF regulates the phototransduction machinery
in rod photoreceptors, similar to light-induced photoreceptor
plasticity [36,38]. Together, these results emphasize the impor-
tance of Mu ¨ller cell-photoreceptor interaction in regulating the
behavior of photoreceptors. This glia-neuron interaction in the
retina may serve as a model of such interaction in other parts of
the nervous system.
In summary, our present study demonstrates the neuroprotec-
tive effects of OSM on photoreceptor degeneration and suggests
the role of Mu ¨ller cells in mediating the protection. Our work
provides additional evidence to support the therapeutic approach
of using members of the IL-6 family of cytokines, especially
Figure 5. Phosphorylation of STAT3 induced by OSM. Eyes of
wild type rats were injected with OSM and retinas were collected at
different time points after injection. OSM-induced STAT3 phosphoryla-
tion as early as 30 min after treatment (A). OSM treatment also induced
an increase in STAT3 protein level in the retina (A). A much smaller
increase in STAT3 phosphorylation with shorter duration was seen in
retinas treated with PBS (B).
doi:10.1371/journal.pone.0018282.g005
Figure 6. Localization of OSM-induced STAT3 phosphorylation.
Retinas (PD20 wild-type rats) were treated with either OSM (left eye) or
PBS (right eye) and harvested 1 hr after injection. Sections were double-
labeled with anti-pSTAT3 antibodies (pSTAT3, green) and antibodies
against glutamine synthetase (GS, red), a Mu ¨ller cell specific marker. No
significant immunoreactivity of pSTAT3 was detected in the control
retina (A and C). OSM treatment induced STAT3 phosphorylation is
colocalized with GS in a group of cells in the INL (D, F). The
colocalization can be clearly seen at a higher magnification (G–I).
Layers of retinas were indicated by vertical white bars (A and D). ONL:
outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer;
IPL: inner plexiform layer, and GCL; ganglion cell layer. Scale bars: 50 mm
for A–F; 30 mm for G–I.
doi:10.1371/journal.pone.0018282.g006
OSM and Photoreceptor Protection
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clinical trials showed that CNTF treatment (CNTF-secreting
implants) improves vision and stops the loss of cones in patients
with retinal degeneration and geographic atrophy [5,39,40]. The
clinical results demonstrate that neuroprotection is a viable
approach for treating retinal degenerative disorders.
Materials and Methods
Ethics Statement
All procedures involving animals adhered to Association for
Research in Vision and Ophthalmology Statement for the Use of
Animals in Ophthalmic and Vision Research and were approved
by the Institutional Animal Care and Use Committee of University
of Miami, Miller School of Medicine (07-174).
Expression and Purification of Human Recombinant OSM
Protein
The open reading frame of mature human OSM cDNA was
cloned by PCR and subcloned into the expression vector pQE30
(Qiagen, Valencia, CA), fused to a 6xHis tag at the N-terminus to
generate plasmid pQE-OSM. Recombinant human OSM protein
was expressed in E. coli (XL-blue; Stratagene, La Jolla, CA) and
purified by immobilized-metal affinity chromatography on Ni-
NTA agarose columns (Qiagen) under native conditions. Eluted
protein was buffer-exchanged to PBS, and stored at 280uCi n
small aliquots. The purified recombinant protein has an apparent
size of about 25 kD after electrophoresis (Fig. 1).
Animals and Intravitreal Injections
Transgenic S334ter-3 rats (Sprague-Dawley background) carry-
ing a murine rhodopsin mutant S334ter [18] and wild-type
Sprague-Dawley (Charles River Labs, Wilmington, MA) rats were
usedinallexperiments.HeterozygousS334ter-3ratswere produced
by mating homozygous male breeders with wild-type Sprague-
Dawley females. Intravitreal injections were delivered through 33-
gauge needles connected to 10-ml microsyringes (Hamilton, Reno,
NV), as described previously [36]. The left eye of an animal was
injected with OSM protein and the right eye with PBS.
Histology, PNA Staining, and Immunocytochemistry
Animals at a given endpoint were killed by CO2 overdose,
immediately followed by vascular perfusion with mixed aldehydes
[18]. Eyes were embedded in an Epon/Araldite mixture, sectioned
at 1 mm thickness to display the entire retina along the vertical
meridian. Retina sections were examined by light microscopy.
Cone outer segments were identified by PNA staining, as
described previously [19]. Briefly, animals were killed by CO2
inhalation and perfused with PBS. Retina-lens preparations were
post-fixed in cold 4% paraformaldehyde solution for 4 hours at
4uC. After rinse in PBS, the retina-lens preparations were
incubated with Alexa fluor 488-conjugate PNA (Invitrogen,
Carlsbad, CA). Retinas were flat-mounted on slides after lenses
were removed and examined by confocal microscopy.
For immunostaining, animals were killed by CO2 inhalation
and perfused with 4% paraformaldehyde. Eyecups were obtained,
cryoprotected with 30% sucrose, embedded in the OCT
compound (Tissue-Tek; Miles Inc., Elkhart, IN), and frozen in
liquid nitrogen. Cryo-sections (12 mm) were incubated with anti-
phospho-STAT3 (Tyr705) antibodies (Cell Signaling Technology,
Beverly, MA). Immunoreactivity was visualized using the ABC
Elite kit (Vector Laboratories, Burlingame, CA) and the Tyramide
Signal Amplification Detection System (Invitrogen) according to
manufacturers’ instructions. Mu ¨ller cells were identified by
antibodies against glutamine synthetase (GS; Millipore Corpora-
tion, Temecula, CA). GS immunoreactivity was visualized by Cy3-
conjugated secondary antibodies (Jackson Immunoresearch; West
Grove, PA). Sections were examined by confocal microscopy.
Immunoblotting Analysis
Retinas were dissected, snap-frozen in powdered dry ice, and
stored at 280uC. Retinas were homogenized and concentration of
total protein in each sample was determined by the Bio-Rad
protein assay (Bio-Rad Labs, Hercules, CA). Total protein of
20 mg from each sample was electrophoresed in 10% NuPAGE
gels (Invitrogen) and transferred to nitrocellular membranes (Bio-
Rad Labs). Blots were probed with anti-phosphorylated STAT3
(Tyr705) antibodies (Cell Signaling Technology), visualized using
SuperSignal chemiluminescent substrates (Thermo Fisher Scien-
tific) and recorded on Hyperfilm (GE Healthcare, Piscataway, NJ).
Blots were then stripped and re-probed with anti-STAT3
antibodies (Cell Signaling Technology).
Statistical Analysis
Results were analyzed by either Student t test or ANOVA
followed by Tukey test for comparisons between different groups,
using InStat3 (GraphPad Software Inc., San Diego, CA). Data are
expressed as mean 6 SD.
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